Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00998049 · OUTCOME

CD34 Yield Day 2

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant · Source last updated 2015-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
cells/kg
Interval / dispersion
Full Range
Time frame
Day 2

What was measured

Number of CD34 cells/kg collected on day 2

Groups in this outcome

Plerixafor

Plerixafor 160mg/kg/dose by IV on days 5-8 Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Plerixafor39

Reported measurements

Source class 1
Values in cells/kg · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Plerixafor3550000Not reported4700009170000Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        470000
        upper Limit
        9170000
        value
        3550000
denoms
  1. counts
    1. group Id
      OG000
      value
      39
    units
    Participants
description
Number of CD34 cells/kg collected on day 2
dispersion Type
Full Range
groups
  1. description
    Plerixafor 160mg/kg/dose by IV on days 5-8 Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
    id
    OG000
    title
    Plerixafor
param Type
MEDIAN
reporting Status
POSTED
time Frame
Day 2
title
CD34 Yield Day 2
type
SECONDARY
unit Of Measure
cells/kg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice